Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Mar 27;8:316. doi: 10.3389/fimmu.2017.00316

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 Barbarin, Cayssials, Jacomet, Nunez, Basbous, Lefèvre, Abdallah, Piccirilli, Morin, Lavoue, Catros, Piaggio, Herbelin and Gombert.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Innate CD8(+) T cells are present in tumors and tumor fluids from ovarian cancer patients. Cells from tumors, carcinoma, peritoneal ascites, and peripheral blood mononuclear cells (PBMCs) from ovarian cancer patients and PBMCs from healthy individuals [healthy donors (HDs)] were analyzed ex vivo by flow cytometry. (A) Two representative samples reflecting the presence of innate CD8(+) T cells in tumor, carcinoma, peritoneal ascites, and PBMCs from ovarian cancer patients and PBMCs from two HDs. ND, not determined. (B) Cohort study of innate CD8(+) T-cell frequency [expressed as percentage ± SD of T cells among total CD8(+) T cells] in tumors (n = 7), carcinoma (n = 7), peritoneal fluids (n = 12), and PBMCs from ovarian cancer patients (n = 10) and PBMCs from HDs (n = 8). (C) Eomes and promyelocytic leukemia zinc-finger factor (PLZF) expression were analyzed in innate CD8(+) T cells [CD3(+) CD8(+) KIR/NKG2A(+) Eomes(+) cells] and iNKT cells [CD3(+) 6B11(+) cells], respectively. Eomes MFI values are expressed relative to that of CD45(+) CD3(−) KIR/NKG2A(−) cells. The MFI of PLZF-expressing iNKT cells correlate positively with Eomes MFI in innate CD8(+) T both in tumor and PBMCs but not in carcinosis (r = −0.04673, p = 0.8853) and ascites (r = 0.5424, p = 0.2084) from ovarian cancer patients (correlation Spearman test). (D) Clinical patient characteristics. NA, not available.

Innate CD8(+) T cells are present in tumors and tumor fluids from ovarian cancer patients. Cells from tumors, carcinoma, peritoneal ascites, and peripheral blood mononuclear cells (PBMCs) from ovarian cancer patients and PBMCs from healthy individuals [healthy donors (HDs)] were analyzed ex vivo by flow cytometry. (A) Two representative samples reflecting the presence of innate CD8(+) T cells in tumor, carcinoma, peritoneal ascites, and PBMCs from ovarian cancer patients and PBMCs from two HDs. ND, not determined. (B) Cohort study of innate CD8(+) T-cell frequency [expressed as percentage ± SD of T cells among total CD8(+) T cells] in tumors (n = 7), carcinoma (n = 7), peritoneal fluids (n = 12), and PBMCs from ovarian cancer patients (n = 10) and PBMCs from HDs (n = 8). (C) Eomes and promyelocytic leukemia zinc-finger factor (PLZF) expression were analyzed in innate CD8(+) T cells [CD3(+) CD8(+) KIR/NKG2A(+) Eomes(+) cells] and iNKT cells [CD3(+) 6B11(+) cells], respectively. Eomes MFI values are expressed relative to that of CD45(+) CD3(−) KIR/NKG2A(−) cells. The MFI of PLZF-expressing iNKT cells correlate positively with Eomes MFI in innate CD8(+) T both in tumor and PBMCs but not in carcinosis (r = −0.04673, p = 0.8853) and ascites (r = 0.5424, p = 0.2084) from ovarian cancer patients (correlation Spearman test). (D) Clinical patient characteristics. NA, not available.